A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease‑Modifying Therapies (RA-BE-REAL) | HMA-EMA Catalogues of real-world data sources and studies